Infect Immun, April 1998, p. 1277-1281, Vol. 66, No. 4
Department of Medicine, Division of
Infectious Diseases, University of California, San Francisco, and
Rosalind Russell Research Laboratory and Loewenstein Laboratory for
Mycobacterial Research, San Francisco General Hospital, San
Francisco, California
The resurgence of concern about
tuberculosis has resulted in the discovery that Mycobacterium
tuberculosis, a facultative intracellular pathogen, has developed
numerous mechanisms for entering human macrophages. In this regard
M. tuberculosis differs from obligate extracellular
pathogens, such as Neisseria species, which have evolved
mechanisms for avoiding entry into phagocytes. This review summarizes
recent studies of macrophage receptors involved in the uptake of
Mycobacterium tuberculosis as well as the current state of
knowledge of events that follow entry through a specific
receptor-mediated pathway, including bacterial survival, phagosome
trafficking, and activation of signal transduction pathways. In
particular, it is meant to stimulate further efforts to determine why a
pathogenic bacterium that can survive and replicate extracellularly has
evolved multiple mechanisms to gain entry to the intracellular environment of the cells that are meant to kill it.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
MINIREVIEW
Macrophage Receptors for Mycobacterium
tuberculosis
![]()
INTRODUCTION
Top
Introduction
References
Phagocyte complement receptors occur in two distinct structural
forms. Complement receptor type 1 (CR1) is a monomeric transmembrane protein that binds C3b and C4b but not C3bi (1). CR1
possesses complement regulatory activity and can mediate phagocytosis
of bound particles, but its capacity for signal transduction or cell activation has not been thoroughly characterized. CR3 and CR4 are
heterodimeric proteins of the integrin superfamily. They are heterodimers that contain identical
subunits (CD18 or
2 integrin) and distinct
subunits (CD11b or
M and CD11c or
X). CR3 and CR4 bind C3bi,
and CR3 also contains a glycan binding site (41). During
maturation of blood monocytes to alveolar macrophages, expression of
CR3 decreases while that of CR4 increases (2, 16).
Like many other bacteria and fungi, M. tuberculosis can activate the alternative pathway of complement activation, resulting in opsonization with C3b and C3bi (31). Bacteria that are sufficiently coated with these serum-derived ligands bind to CR1, CR3, and CR4 and are subsequently phagocytosed in membrane-bound phagosomes (16, 30, 31). Unlike other bacteria (Staphylococcus aureus and Listeria monocytogenes) or other intramacrophage pathogens, such as Leishmania mexicana, pathogenic mycobacteria, including M. tuberculosis, have developed an additional mechanism for acquiring opsonic C3 peptides. Pathogenic mycobacteria uniquely recruit the complement fragment C2a to form a C3 convertase and generate opsonically active C3b in the absence of early activation components of the alternative or classical pathways (34). It appears that the predominant opsonin generated by scavenging C2a is C3b, rather than C3bi, as mycobacteria that are opsonized by this mechanism bind predominantly to CR1 rather than to CR3 or CR4.
As if it were not enough for M. tuberculosis to acquire
opsonic C3 peptides by at least two distinct mechanisms, M. tuberculosis can bind to CR3 at two distinct sites on the
receptor. Opsonized M. tuberculosis binds CR3 at its C3bi
binding domain, and nonopsonized M. tuberculosis uses its
endogenous capsular polysaccharides to interact with the
-glucan
binding site near the C terminus of CD11b (9, 10).
Experiments using human monocytes and murine macrophages had strongly
implied that there is more than one mode of interaction between
M. tuberculosis and CR3 (31, 37), but unambiguous
evidence that nonopsonic (i.e., C3bi-independent) interactions occur
was obtained in studies in which CR3 was expressed in a nonmacrophage
background, so that endogenous synthesis of C3 by macrophages could not
interfere. Chinese hamster ovary (CHO) cells stably transfected with
CD18 and CD11b bind a strain of M. tuberculosis H37Rv
("CC") in a serum-independent manner, and binding of this strain is
not enhanced by fresh human or bovine serum (9). A
monoclonal antibody that blocks the C3bi binding site in the I domain
of CD11b does not block binding of H37Rv-CC to transfected CHO cells,
whereas an antibody to an alternative site within the I domain and an
antibody to the C-terminal domain do block binding to CR3 expressed on
CHO cells. Further analysis has revealed that distinct strains and
substrains of M. tuberculosis vary in their predominant mode
of interaction with CR3. For example, H37Rv-CC, M. tuberculosis Erdman, and four of five clinical isolates examined
bind purely or predominantly by a C3bi-independent mechanism, while a
distinct H37Rv substrain, H37Rv-HH, and one of five clinical isolates
examined binds CR3 only after opsonization with C3bi (10).
Nonopsonic binding of M. tuberculosis to CR3 is inhibited by
laminarin (a seaweed-derived
-glucan), by
N-acetyl-D-glucosamine, or by purified M. tuberculosis capsular glucan or mannan but not by capsular
arabinomannan or yeast mannan. Moreover, mild mechanical extraction of
capsular polysaccharides or treatment with amyloglucosidase markedly
reduces nonopsonic binding, implying that the bacterial ligands for
this domain of CR3 are peripherally located capsular carbohydrate
residues. These studies clearly show that individual strains of
M. tuberculosis can vary in their modes of interaction with
CR3 and that they interact with distinct domains of the receptor. These
results are consistent with the results of studies of the polysaccharide specificity of the
-glucan binding site(s) of CR3
(41). Whether binding to one site on CR3 or the other is advantageous to the bacteria remains to be determined, but engagement of both domains of CR3 on neutrophils or NK cells results in activation of cellular responses, while engagement of the C3bi binding alone does
not (42). In summary, M. tuberculosis can exploit
complement receptors through multiple mechanisms to bind to and enter
macrophages. The mechanism and consequences that predominate in vivo
may be determined by features of the individual bacterial strain
(complement dependent or independent), the environment of the
macrophage (such as the availability of complement proteins), and the
state of differentiation or activation of the macrophage.
Currently, little is known about the trafficking of phagosomes that contain bacteria or model particles ingested by macrophages through complement receptors. As the understanding of phagosome trafficking and maturation expands, it will be of interest to determine whether the kinetics, order, and extent of phagosome interactions with the endocytic and exocytic pathways are distinct for phagocytosis mediated by complement receptors compared to that by other phagocytic receptors.
MANNOSE RECEPTORHuman monocyte-derived macrophages bind and internalize virulent
M. tuberculosis via mannose receptors (30). A
quantitatively important role for mannose receptors in binding and
phagocytosis of M. tuberculosis was demonstrated by
competitive inhibition, downregulation of apical mannose receptors by
adherence of macrophages to mannan-coated coverslips, and blocking with
a polyclonal anti-mannose receptor antibody (30). Of note,
mannose receptors bind the virulent Erdman and H37Rv strains but not
the avirulent H37Ra strain. While it is currently unclear whether
M. tuberculosis contains other ligands for mannose
receptors, one well-characterized ligand is lipoarabinomannan (LAM),
which is abundant and peripherally exposed and contains terminal
mannose residues that interact with mannose receptors (32,
33). Multiple biological responses have been attributed to LAM,
but is not clear whether these are mediated through mannose receptors,
since LAM can also interact with other receptors on macrophages,
including CD14 (see below). The expression of mannose receptors is
downregulated by gamma interferon (35, 36); therefore, their
role in ingestion of M. tuberculosis early in infection or
in individuals with compromised cellular immunity may be more important
than in established granulomas. In addition to a role for mannose
receptors in phagocytosis of whole bacteria, these receptors can
mediate delivery of LAM to endocytic compartments that contain CD1b,
thereby facilitating presentation of mycolic acid and lipoglycan
antigens to CD4
CD8
T cells or
CD8+ T cells (27).
Sp-A enhances macrophage binding and uptake of M. tuberculosis, although the mechanisms of these phenomena have not been fully elucidated (12). Purified Sp-A binds directly to M. tuberculosis H37Ra, and binding to the bacteria is dependent on calcium and on glycosylation of Sp-A (25). Trypsin treatment of M. tuberculosis decreases binding of Sp-A, and in membrane overlay experiments, Sp-A binds to a 60-kDa protein in crude cell wall extracts of M. tuberculosis. The specificity of this interaction remains to be established, as it is unclear whether the interaction with the 60-kDa protein is dependent on calcium or on Sp-A glycosylation, and a 60-kDa protein was the most abundant protein in the cell wall extract used in the overlay assay. While type V collagen blocks binding of M. tuberculosis to murine lung macrophages, it does not block binding of Sp-A to M. tuberculosis. This finding suggests that Sp-A can operate as an opsonin, binding to M. tuberculosis by the N-linked polysaccharides of Sp-A and to macrophages by the collagen-like domain. It will be interesting to learn the identity of the receptor(s) that mediates attachment of Sp-A-coated M. tuberculosis to murine alveolar macrophages.
In experiments with human monocyte-derived macrophages and alveolar macrophages, different results have been obtained. In this system, Sp-A enhances binding and phagocytosis of M. tuberculosis (Erdman) to macrophages, but pretreatment of the macrophages followed by washing is as effective as simultaneous incubation of macrophages with M. tuberculosis and Sp-A (15). This finding suggests that Sp-A is not simply acting as an opsonin and may be modulating the activity of one or more receptors that are responsible for directly binding M. tuberculosis. Mannose receptors account for some of this binding activity, as indicated by the ability of yeast mannan or a polyclonal antibody to the mannose receptor to abrogate the effects of Sp-A in enhancing M. tuberculosis binding. Sp-A also binds to Mycobacterium bovis BCG and enhances the binding and phagocytosis of BCG to rat pulmonary macrophages and human monocytes. A polyclonal antibody to the Sp-A receptor SPR210 blocks the binding of Sp-A-coated BCG to macrophages and monocytes (44).
While it is clear that Sp-A enhances interactions of M. tuberculosis and macrophages, the mechanisms and cognate receptors demand further study. At a minimum, Sp-A can act as an opsonin that allows recognition of mycobacteria, but the identities of macrophage receptors that account for this recognition remain incompletely defined. Monospecific blocking reagents and heterologous expression of C1qRP and SPR210 need to be applied to this problem, and CR1 (CD35) warrants further study as a candidate Sp-A receptor. In addition to serving as an opsonin, there is also evidence that Sp-A can enhance ingestion of particles including M. tuberculosis by other mechanisms. Attachment of macrophages to Sp-A-coated surfaces enhances phagocytosis by Fc and complement receptors (40) and probably by mannose receptors (15). That this mechanism extends to such structurally diverse receptors makes it improbable that Sp-A interacts physically with each of these receptors. It is more likely that this effect of Sp-A is exerted at a step in phagocytosis that is common to and downstream of various receptors, but a full understanding of this effect awaits directed mechanistic studies.
OTHER RECEPTORSScavenger receptors. Macrophage scavenger receptors bind polyanionic macromolecules and particles, including lipopolysaccharides of gram-negative bacteria and lipoteichoic acid of gram-positive bacteria (13, 20). Experiments using competitive inhibitors have implicated class A scavenger receptors as quantitatively important receptors for M. tuberculosis (Erdman) on human monocyte-derived macrophages (46). Moreover, purified class A scavenger receptors bind M. tuberculosis, and sulfolipids (sulfatides) from M. tuberculosis compete with other ligands for class A scavenger receptor binding while LAM does not (17a). It is not yet known whether scavenger receptors can activate the cytoskeleton to internalize bacteria or, alternatively, whether scavenger receptors act to bind bacteria but phagocytosis is executed by other receptors.
Fc
receptors.
Some infected individuals have circulating
antibodies to M. tuberculosis (21), and one study
has demonstrated that the intracellular trafficking of M. tuberculosis (H37Rv) opsonized with immune serum is distinct from
that of nonopsonized bacteria. Immunoglobulin G (IgG)-coated
mycobacteria were ingested by macrophages in vesicles that
readily fused with ferritin-loaded lysosomes, whereas unopsonized mycobacteria resided in phagosomes that did not acquire ferritin from
labeled lysosomes (3). Despite the fusion with labeled lysosomes, IgG-opsonized mycobacteria survived intracellularly at the
same rate as did nonopsonized bacteria. This finding implies that entry
through Fc
receptors may specify a distinct intracellular trafficking pathway for virulent M. tuberculosis but that
this alteration of intracellular trafficking does not affect the
intracellular growth of the bacteria. Perhaps this helps explain the
lack of benefit conferred by passive transfer of immune serum in
experimental tuberculosis.
receptors and CR3 markedly facilitates phagocytosis of IgG-opsonized
targets (19). Such cooperation may account for phagocytosis
of particles bound to receptors that lack transmembrane and cytoplasmic
domains, such as CD14.
DOES THE RECEPTOR-MEDIATED ROUTE OF ENTRY OF M. TUBERCULOSIS AFFECT SUBSEQUENT EVENTS?
It is also possible that distinct routes of entry of M. tuberculosis dictate activation of distinct cytokine secretion responses by macrophages. These responses may result in distinct outcomes that are important in vivo but would not have been detected in the aforementioned study that examined mycobacterial survival and replication in vitro.
A MYCOBACTERIAL RATIONALE FOR USE OF MULTIPLE RECEPTORSIn summary, M. tuberculosis has developed a large number of mechanisms to enter human macrophages. Evidence to date implies that individual entry pathways do not have a major influence on intracellular survival and growth of the bacteria, but distinct receptor-mediated pathways may dictate differences that will be revealed by careful examination of phagosome trafficking or that are only evident in vivo. On the other hand, M. tuberculosis may not care how it enters macrophages, only that it does. Distinguishing these possibilities should be examined in future studies. Further studies should also consider whether intracellular trafficking of M. tuberculosis phagosomes is affected by the route of entry and whether macrophage responses to M. tuberculosis are activated differently if the macrophages meet the bacteria through distinct receptors. Recent work has provided much information on initial M. tuberculosis-macrophage interactions. Considerable additional work will be required to understand the consequences of this complex interaction.
| |
ACKNOWLEDGMENT |
|---|
This work was supported in part by NIH grant HL51992.
| |
FOOTNOTES |
|---|
Mailing address: UCSF, Box 0868, San Francisco, CA 94143-0868. Phone: (415) 206-6647. Fax: (415) 648-8425. E-mail: joel{at}cgl.ucsf.edu.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ahearn, J. M., and D. T. Fearon. 1989. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 46:183-219[Medline]. |
| 2. | Albert, R. K., L. J. Embree, J. E. McFeely, and D. D. Hickstein. 1992. Expression and function of beta 2 integrins on alveolar macrophages from human and nonhuman primates. Am. J. Respir. Cell. Mol. Biol. 7:182-189. |
| 3. |
Armstrong, J. A., and P. D. A. Hart.
1975.
Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival.
J. Exp. Med.
142:1-16 |
| 4. | Bermudez, L. E., A. Parker, and J. R. Goodman. 1997. Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway. Infect. Immun. 65:1916-1925[Abstract]. |
| 5. |
Chroneos, Z., and V. L. Shepherd.
1995.
Differential regulation of the mannose and SP-A receptors on macrophages.
Am. J. Physiol.
269:L721-L726 |
| 6. |
Chroneos, Z. C.,
R. Abdolrasulnia,
J. A. Whitsett,
W. R. Rice, and V. L. Shepherd.
1996.
Purification of a cell-surface receptor for surfactant protein A.
J. Biol. Chem.
271:16375-16383 |
| 7. | Cirillo, J. D., S. Falkow, L. S. Tompkins, and L. E. Bermudez. 1997. Interaction of Mycobacterium avium with environmental amoebae enhances virulence. Infect. Immun. 65:3759-3767[Abstract]. |
| 8. |
Clemens, D. L., and M. A. Horwitz.
1995.
Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited.
J. Exp. Med.
181:257-270 |
| 9. | Cywes, C., N. L. Godenir, H. C. Hoppe, R. R. Scholle, L. M. Steyn, R. E. Kirsch, and M. R. Ehlers. 1996. Nonopsonic binding of Mycobacterium tuberculosis to human complement receptor type 3 expressed in Chinese hamster ovary cells. Infect. Immun. 64:5373-5383[Abstract]. |
| 10. | Cywes, C., H. C. Hoppe, M. Daffe, and M. R. Ehlers. 1997. Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Infect. Immun. 65:4258-4266[Abstract]. |
| 11. | Da Silva, R. P., B. F. Hall, K. A. Joiner, and D. L. Sacks. 1989. CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages. J. Immunol. 143:617-622[Abstract]. |
| 12. |
Downing, J. F.,
R. Pasula,
J. R. Wright,
H. L. Twigg III, and W. J. Martin, II.
1995.
Surfactant protein A promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
92:4848-4852 |
| 13. |
Dunne, D. W.,
D. Resnick,
J. Greenberg,
M. Krieger, and K. A. Joiner.
1994.
The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid.
Proc. Natl. Acad. Sci. USA
91:1863-1867 |
| 14. |
Ezekowitz, R. A.,
K. Sastry,
P. Bailly, and A. Warner.
1990.
Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells.
J. Exp. Med.
172:1785-1794 |
| 15. | Gaynor, C. D., F. X. McCormack, D. R. Voelker, S. E. McGowan, and L. S. Schlesinger. 1995. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J. Immunol. 155:5343-5351[Abstract]. |
| 16. | Hirsch, C. S., J. J. Ellner, D. G. Russell, and E. A. Rich. 1994. Complement receptor-mediated uptake and tumor necrosis factor alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J. Immunol. 152:743-753[Abstract]. |
| 17. | Ishibashi, Y., and T. Arai. 1990. Roles of the complement receptor type 1 (CR1) and type 3 (CR3) on phagocytosis and subsequent phagosome-lysosome fusion in Salmonella-infected murine macrophages. FEMS Microbiol. Immunol. 2:89-96[Medline]. |
| 17a. | Joiner, K., and M. Krieger. Personal communication. |
| 18. | Klickstein, L. B., S. F. Barbashov, T. Liu, R. M. Jack, and A. Nicholson-Weller. 1997. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 7:345-355[Medline]. |
| 19. | Krauss, J., C. PooH, W. Xue, L. Mayo-Bond, R. F. Todd III, and H. R. Petty. 1994. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. J. Immunol. 153:1769-1777[Abstract]. |
| 20. |
Krieger, M.,
S. Acton,
J. Ashkenas,
A. Pearson,
M. Penman, and D. Resnick.
1993.
Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors.
J. Biol. Chem.
268:4569-4572 |
| 21. | Laal, S., K. M. Samanich, M. G. Sonnenberg, J. T. Belisle, J. O'Leary, M. S. Simberkoff, and S. Zolla-Pazner. 1997. Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J. Infect. Dis. 176:133-143[Medline]. |
| 22. | McDonough, K. A., and Y. Kress. 1995. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63:4802-4811[Abstract]. |
| 23. | Mosser, D. M., and P. J. Edelson. 1987. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 327:329-331[Medline]. |
| 24. | Nepomuceno, R. R., A. H. Henschen-Edman, W. H. Burgess, and A. J. Tenner. 1997. cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity 6:119-129[Medline]. |
| 25. |
Pasula, R.,
J. F. Downing,
J. R. Wright,
D. L. Kachel,
T. E. Davis, Jr., and W. J. N. Martin.
1997.
Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages.
Am. J. Respir. Cell. Mol. Biol.
17:209-217 |
| 26. | Peterson, P. K., G. Gekker, S. Hu, W. S. Sheng, W. R. Anderson, R. J. Ulevitch, P. S. Tobias, K. V. Gustafson, T. W. Molitor, and C. C. Chao. 1995. CD14 receptor-mediated uptake of nonopsonized Mycobacterium tuberculosis by human microglia. Infect. Immun. 63:1598-1602[Abstract]. |
| 27. | Prigozy, T. I., P. A. Sieling, D. Clemens, P. L. Stewart, S. M. Behar, S. A. Porcelli, M. B. Brenner, R. L. Modlin, and M. Kronenberg. 1997. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Immunity 6:187-197[Medline]. |
| 28. | Pugin, J., I. D. Heumann, A. Tomasz, V. V. Kravchenko, Y. Akamatsu, M. Nishijima, M. P. Glauser, P. S. Tobias, and R. J. Ulevitch. 1994. CD14 is a pattern recognition receptor. Immunity 1:509-516[Medline]. |
| 29. | Savedra, R., Jr., R. L. Delude, R. R. Ingalls, M. J. Fenton, and D. T. Golenbock. 1996. Mycobacterial lipoarabinomannan recognition requires a receptor that shares components of the endotoxin signaling system. J. Immunol. 157:2549-2554[Abstract]. |
| 30. | Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150:2920-2930[Abstract]. |
| 31. | Schlesinger, L. S., C. G. Bellinger-Kawahara, N. R. Payne, and M. A. Horwitz. 1990. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 144:2771-2780[Abstract]. |
| 32. | Schlesinger, L. S., S. R. Hull, and T. M. Kaufman. 1994. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J. Immunol. 152:4070-4079[Abstract]. |
| 33. | Schlesinger, L. S., T. M. Kaufman, S. Iyer, S. R. Hull, and L. K. Marchiando. 1996. Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J. Immunol. 157:4568-4575[Abstract]. |
| 34. |
Schorey, J. S.,
M. C. Carroll, and E. J. Brown.
1997.
A macrophage invasion mechanism of pathogenic mycobacteria.
Science
277:1091-1093 |
| 35. | Schreiber, S., S. L. Perkins, S. L. Teitelbaum, J. Chappel, P. D. Stahl, and J. S. Blum. 1993. Regulation of mouse bone marrow macrophage mannose receptor expression and activation by prostaglandin E and IFN-gamma. J. Immunol. 151:4973-4981[Abstract]. |
| 36. | Shepherd, V. L., H. B. Cowan, R. Abdolrasulnia, and S. Vick. 1994. Dexamethasone blocks the interferon-gamma-mediated downregulation of the macrophage mannose receptor. Arch. Biochem. Biophys. 312:367-374[Medline]. |
| 37. | Stokes, R. W., I. D. Haidl, W. A. Jefferies, and D. P. Speert. 1993. Mycobacteria-macrophage interactions. Macrophage phenotype determines the nonopsonic binding of Mycobacterium tuberculosis to murine macrophages. J. Immunol. 151:7067-7076[Abstract]. |
| 38. | Sutterwala, F. S., L. A. Rosenthal, and D. M. Mosser. 1996. Cooperation between CR1 (CD35) and CR3 (CD 11b/CD18) in the binding of complement-opsonized particles. J. Leukoc. Biol. 59:883-890[Abstract]. |
| 39. |
Taylor, M. E., and K. Drickamer.
1993.
Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor.
J. Biol. Chem.
268:399-404 |
| 40. |
Tenner, A. J.,
S. L. Robinson,
J. Borchelt, and J. R. Wright.
1989.
Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis.
J. Biol. Chem.
264:13923-13928 |
| 41. | Thornton, B. P., V. Vetvicka, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235-1246[Abstract]. |
| 42. | Vetvicka, V., B. P. Thornton, and G. D. Ross. 1996. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:50-61[Medline]. |
| 43. |
Via, L. E.,
D. Deretic,
R. J. Ulmer,
N. S. Hibler,
L. A. Huber, and V. Deretic.
1997.
Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7.
J. Biol. Chem.
272:13326-13331 |
| 44. |
Weikert, L. F.,
K. Edwards,
Z. C. Chroneos,
C. Hager,
L. Hoffman, and V. L. Shepherd.
1997.
SP-A enhances uptake of bacillus Calmette-Guerin by macrophages through a specific SP-A receptor.
Am. J. Physiol.
272:L989-L995 |
| 45. | Xu, S., A. Cooper, S. Sturgill-Koszycki, T. van Heyningen, D. Chatterjee, I. Orme, P. Allen, and D. G. Russell. 1994. Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J. Immunol. 153:2568-2578[Abstract]. |
| 46. | Zimmerli, S., S. Edwards, and J. D. Ernst. 1996. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am. J. Respir. Cell. Mol. Biol. 15:760-770[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|